Taken together, these data uncover a regulatory loop initiated by ADT-induced HGF/MET and Wnt/β-catenin signaling activation through dysregulation of XPO1-regulated nuclear export, ribosomal biogenesis, and protein synthesis to promote tumor progression, hormone refractoriness, and DNPC development (Fig. 7i), providing scientific evidence for targeting nuclear export and ribosomal synthesis in combination with current ADT for future therapies. The gene discussed is XPO1; the disease is neoplasm.